ELAN logo

Elanco Animal Health Incorporated (ELAN)

$25.85

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ELAN

Market cap

$12.92B

EPS

-0.29

P/E ratio

--

Price to sales

2.28

Dividend yield

--

Beta

1.732779

Price on ELAN

Previous close

$26.41

Today's open

$26.32

Day's range

$25.74 - $26.80

52 week range

$19.40 - $27.98

Profile about ELAN

CEO

Jeffrey N. Simmons

Employees

9400

Headquarters

INDIANAPOLIS, IN

Exchange

New York Stock Exchange

Shares outstanding

499827067

Issue type

Common Stock

ELAN industries and sectors

Healthcare

Pharmaceuticals

News on ELAN

Elanco to Participate in Upcoming Investor Conferences

INDIANAPOLIS, Nov. 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Monday, November 30, Jeff Simmons, president and CEO, will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference at 12:55 p.m.

news source

PRNewsWire • 5 hours ago

news preview

Elanco Animal Health: 3 Key Takeaways for Long-Term Investors

Third-quarter organic constant currency revenue grew 9% year over year. Elanco Animal Health lowered gross debt by $216 million in Q3.

news source

The Motley Fool • Nov 9, 2026

news preview

Elanco Animal Health Incorporated (ELAN) Presents at 2026 UBS Global Healthcare Conference Transcript

Elanco Animal Health Incorporated ( ELAN ) 2026 UBS Global Healthcare Conference November 9, 2026 1:15 PM EST Company Participants Robert VanHimbergen - Executive VP & CFO Rajeev Modi - Executive Vice President of U.S. Pet Health & Global Digital Transformation Conference Call Participants Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Presentation Andrea Zayco Narvaez Alfonso UBS Investment Bank, Research Division So good afternoon, everybody. I'm Andrea Alfonso.

news source

Seeking Alpha • Nov 9, 2026

news preview

Elanco Animal Health Q3 Earnings Call Highlights

Elanco Animal Health NYSE: ELAN raised its full-year outlook after third-quarter revenue rose 11%, driven by demand for its pet health products Zenrelia and Credelio Quattro and higher prices across its portfolio.

news source

MarketBeat • Nov 7, 2026

news preview

Elanco Animal Health Incorporated (ELAN) Q3 2026 Earnings Call Transcript

Elanco Animal Health Incorporated ( ELAN ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Tiffany Kanaga - VP of Investor Relations & ESG Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Glen Santangelo - Barclays Bank PLC, Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Christopher LoBianco - TD Cowen, Research Division Presentation Operator Good day, and welcome to Elanco Animal Health Reports Third Quarter 2026 Results.

news source

Seeking Alpha • Nov 6, 2026

news preview

Elanco Animal Health Reports Third Quarter 2026 Results

Accelerated Price, Organic Constant Currency Revenue Growth, and Gross Margin Expansion; Raising Full Year Outlook and Innovation Target; Achieved 2.9x Net Leverage Ratio Milestone Third Quarter 2026 Financial Results: Revenue of $1.265 billion, an increase of 11% year-over-year; 9% organic constant currency growth Reported Net Income of $18 million, Adjusted Net Income of $136 million Adjusted EBITDA of $243 million; Adjusted EBITDA Margin of 19.5% Reported EPS of $0.04, Adjusted EPS of $0.27 Net leverage ratio of 2.9x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.275 billion Raising revenue guidance to $5.155 billion to $5.18 billion, or approximately 8% organic constant currency growth Raising Adjusted EBITDA guidance to $1.05 billion to $1.065 billion, a year-over-year increase of 17% at midpoint Raising Adjusted EPS guidance to $1.17 to $1.20, a year-over-year increase of 26% at midpoint Improving year-end net leverage ratio target to approximately 2.9x Adjusted EBITDA with accelerated capital allocation flexibility 2027 Early Outlook: Building on expectations for full year 2026 outperformance, with continued expectation for 2027 results in line with December 2025 Investor Day annual algorithm: mid-single digit organic constant currency revenue growth, high-single digit Adjusted EBITDA growth, and low-double digit Adjusted EPS growth INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2026, provided guidance for the fourth quarter of 2026, updated guidance for the full year 2026, and provided an early outlook for the full year 2027. "Third quarter results demonstrate Elanco is a consistent, reliable growth company, delivering our diverse portfolio of innovation along with accelerating cash flow," stated Jeff Simmons, President and CEO of Elanco.

news source

PRNewsWire • Nov 6, 2026

news preview

Elanco Animal Health Sees Strong Momentum Heading Into 2027

Elanco Animal Health Incorporated (NYSE:ELAN) delivered better-than-expected third-quarter financial results on strong demand and higher prices.

news source

Benzinga • Nov 6, 2026

news preview

Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Surpass Estimates

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.19 per share a year ago.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Elanco Animal Health (ELAN) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Elanco Animal Health (ELAN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 6, 2026

news preview

October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority

Latest U.S. Survey of 2,000+ Consumers Shows 93% of Pet Owners Maintained or Increased Pet Spending in Past Three Months, Omnichannel Shift Redefines Purchasing INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), today released findings from its latest U.S. consumer research, demonstrating that pet owners continue to fiercely protect health spending for their pets, affirming expectations for enduring strength of the animal health sector.  According to the national omnibus survey of 2,018 U.S. consumers, including 1,495 dog and cat owners, fielded in mid-October 2026, pet health and wellness remains an indispensable household priority even as families navigate cost-of-living pressures: Pet Health Remains a Protected Household Priority: Despite broader macro pressures, 93% of pet owners surveyed maintained or increased pet spending over the past three months.

news source

PRNewsWire • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Elanco Animal Health Incorporated

Open an M1 investment account to buy and sell Elanco Animal Health Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ELAN on M1